05.16.25 -- Partners Ready To Support Your Phase 1-3 Trials

Our extensive oncology expertise coupled with an end-to-end approach helps accelerate your clinical programs, giving you the confidence to bring breakthrough treatments to patients.

Avance Clinical has partnerships with high-quality community-based sites and site networks to accelerate start-up timelines and patient recruitment to significantly reduce the cost burden.

With over 140 neuroscience studies completed and specialized expertise in neurodegenerative diseases, TFS brings deep expertise and a proven track record to every trial.

We are a full-service clinical outsourcing company of problem solvers, decision makers, and cross-functional collaborators determined to find a better way to deliver high-quality value.

This premier CRO exemplifies reliability, flexibility, and accessibility for biotech, providing the skills and expertise needed to meet key goals and critical milestones.

Novotech has built teams with deep expertise in oncology and immuno-oncology and strong connections with oncology key opinion leaders and sites in the Asia-Pacific region.

With over 30 years of experience, we provide comprehensive clinical pharmacology services, from data management and analysis to the generation of clinical study reports.

Veristat’s team leverages lessons learned, supporting more than 375 clinical trials and consulting projects, 40 INDs/CTAs, and 20 marketing applications for biologic therapies in the past five years.

Palleos Oncology™ is a comprehensive solution designed to support pharmaceutical companies throughout the entire lifecycle of oncology treatment development.

Choosing the right CRO/CDMO for your first-in-human (FIH) trials enables you to run a successful study that generates high-quality data with speed and ease.

A successful trial starts with an efficient protocol review. With deep roots in academic research and clinical medicine, BRANY IRB is uniquely positioned to meet your cost and speed requirements.

How can Ergomed use its oncology expertise, global reach, and access to patients with rare and ultra-rare diseases can help your organization achieve efficient, high-quality clinical trial execution?